JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Intra-abdominal infections.

Most intra-abdominal infections develop from a source in the gastrointestinal tract. They are usually caused by aerobic and anaerobic enteric bacteria. Management generally involves an invasive procedure to control the source of the infection and antimicrobial therapy directed against the causative microorganisms. In a few highly select patients, these infections may be treated without a definitive source control procedure. Antimicrobial therapy is tailored to the individual patient, with narrower spectrum agents used to treat community-acquired intraabdominal infections, and broader spectrum agents used for hospital-acquired infections. Overall, these infections remain associated with significant morbidity and mortality, particularly in higher-risk patients who have impaired host defenses.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app